Tim Van Hauwermeiren

“Reflecting on where we stand, our GenX has never been better positioned and our leadership transition comes at the right moment as we enter our next phase of growth Karen is a right leader to take this forward she understands our innovation playbook leads with patients at the center of every decision and brings the…”

“At the start of the year, we set a bold growth agenda anchored in our long-term roadmap for value creation, Vision 2030. Today, VYVGART is delivering meaningful impact in two blockbuster indications with MG and CIDP.”

“At Argenx, we are building our company for the long run. Our strategic decision-making paired with an agile approach has positioned us to deliver sustained growth in a dynamic and evolving market landscape.”

“We expanded our reach to over 10,000 patients globally across 3 approved indications and delivered significant impacts to the CIDP community early into launch. We also achieved several key clinical milestones.”

“As we approach the end of 2024, it is incredible to reflect on all that we have accomplished. Having achieved the goals set out in our 2025 vision ahead of plan.”